F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented Myt1 kinase (PKMYT1) inhibitors for the treatment of cancer.

Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.

Cancer Research Technology Ltd. and My-T Bio Ltd. have discovered Myt1 kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.

Shenzhen Bay Laboratory has identified Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Simcere Zaiming Pharmaceutical Co. Ltd. has described membrane‑associated tyrosine‑ and threonine‑specific Cdc2‑inhibitory kinase (PKMYT1) inhibitors for cancer.

Voronoi Inc. has disclosed heteroaryl compounds acting as Myt1 kinase (PKMYT1) and/or Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed compounds acting as Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Sunshine Lake Pharma Co. Ltd. has disclosed Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.